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et al. approached this problem in the brain, an organ that under 
normal homeostasis constantly generates new cells from special-
ized precursor cells, that is, adult, organ-specific stem cells. Ageing 
results in a precipitous decline in neurogenesis and impairment in 
cognitive functions, which, surprisingly and very interestingly, can 
be ameliorated through systemic perturbations such as exercise. 
Villeda et al. used parabiosis between old and young mice (Figure, 
top) and found that blood-borne factors can inhibit or promote 
adult neurogenesis in an age-dependent fashion. They found that 
the number of proliferating cells (BrdU-positive), identified as 
neurons, decreased in young heterochronic parabionts (Figure, 
bottom left), whereas it increased in old heterochronic parabionts 
(Figure, bottom right). Remarkably, exposing young mice to an 
old systemic environment or to plasma from old mice decreased 
synaptic plasticity and impaired fear conditioning, learning, and 
memory. To identify potential blood-borne factors that could be 
involved in these effects, the authors compared the abundance 
of many plasma proteins in young and old mice, work that led 
them to the chemokine CCL11, a cytokine known to be involved 
in allergic responses. Increasing peripheral CCL11 levels in vivo in 
young mice decreased adult neurogenesis and impaired learning 
and memory.
This remarkable article shows that the declines in neurogenesis 
and cognitive function observed during ageing are at least partially 
due to changes in blood-borne factors, factors that are amenable 
to identification and manipulation.
Juan Oliver
Epidermal growth factor receptor 
promotes glomerular injury and 
renal failure in rapidly progressive 
glomerulonephritis
Bollée et al., Nat Med 2011; 17: 1242–1250; doi:10.1038/nm.2491
Rapidly progressive glomerulonephritis (RPGN), or crescentic 
glomerulonephritis, is a life-threatening disease that destroys 
Blood pressure targets 
recommended by guidelines and 
incidence of cardiovascular and 
renal events in the ONTARGET trial
Mancia et al., Circulation 2011; 124: 1727–1736; doi:10.1161/
CIRCULATIONAHA.110.008870
Control of blood pressure (BP) plays an integral part in slow-
ing the progression of kidney disease. Although multiple trials 
have examined different BP targets, no consensus on the tar-
get and what constitutes achievement of the target has been 
reached. The ONTARGET trial randomized participants with 
known atherosclerotic disease or with diabetes and end-organ 
damage to treatment with telmisartan, ramipril, or both. In this 
secondary analysis of ONTARGET, two treatment thresholds 
were considered (<140/90 and <130/80 mm Hg). Participants 
with at least seven visits before reaching one of the primary 
events were grouped on the basis of the proportion of post-ran-
domization visits at which they achieved each of the two tar-
gets (<25%, 25–50%, 50–75%, and >75%). When groups were 
compared, participants with greater proportions of visits below 
the threshold BP value were more likely to have a higher pre-
randomization BP and less likely to have diabetes mellitus. With 
respect to renal end points, participants with greater proportions 
of visits below the threshold BP value were less likely to experi-
ence new microalbuminuria or new macroalbuminuria. When 
the threshold of <140/90 was used, there was a trend toward a 
greater likelihood of normalization of albuminuria among those 
achieving the goal more frequently. However, when a threshold 
of <130/80 was used, the beneficial association was significant.
A cause–effect relationship cannot be concluded from this post 
hoc analysis, as the association may be related to achievement of 
the goal or to something intrinsic to the patient with respect to 
an ability to achieve the goal. Although formal randomized trials 
remain necessary to truly define the benefits of different targets, 
this analysis provides support for the likelihood that a lower goal 
achieved with more consistency may improve renal outcomes.
Lynda Szczech
The ageing systemic milieu 
negatively regulates generation  
of new cells
Villeda et al., Nature 2011; 477: 90–94; doi:10.1038/nature10357
Nobody likes to get old, but we all do. Among many problems, 
ageing decreases the ability of organs to repair from injury. 
Nephrologists are well aware that the probability of recovering 
kidney function after an episode of acute kidney injury markedly 
decreases with advanced age; however, there is no understanding 
of why age should have such an effect. In a recent article, Villeda 
Schematic showing parabiotic pairings (top) and quantification of 
proliferating cells (bottom) in the young (left) and old (right) after 
parabiosis. DG, dentate gyrus.
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kidneys over a period of days, representing one of the few 
diag nostic and therapeutic emergencies in nephrology. Heparin-
binding epidermal growth factor–like growth factor (HB-EGF), 
a member of the EGF family, is expressed during inflammatory 
and pathological conditions. The exact pathophysiological role of 
HB-EGF RPGN has not been clearly defined. HB-EGF is upregu-
lated in vascular endothelial cells by cytokines (interleukin-1b and 
tumor necrosis factor-a) and lysophosphatidylcholine, mediators 
that may be elicited in RPGN. HB-EGF has been detected in con-
ditioned medium of macrophages and macrophage-like U-937 
cells and in CD4+ T cells within atherosclerotic plaques. T cells 
and macrophages have important effec tor roles in promoting the 
formation of destructive cellular cres cents in RPGN. Bollée et al. 
found de novo induction of HB-EGF in intrinsic glomerular epi-
thelial cells (podocytes) from both mice and humans (immunola-
beling of kidney biopsies) with RPGN, eliciting epidermal growth 
factor receptor (EGFR) acti vation primarily in these cells, which, 
in turn, promotes glomerular lesions. HB-EGF induction increases 
phosphorylation of the EGFR (also known as ErbB1) in mice with 
RPGN. In HB-EGF-deficient mice, EGFR activation in glomeruli is 
absent, and the course of RPGN is improved. Autocrine HB-EGF 
induces a phenotypic switch in podocytes in vitro. Conditional 
deletion of the Egfr gene from podocytes of mice alleviates the 
severity of RPGN. Likewise, pharmacological blockade of EGFR 
also improves the course of RPGN, even when started 4 days after 
the induction of experimental RPGN. Although there is some 
discussion in the literature on the protective or deleterious role 
of activation of HB-EGF, the authors convincingly demonstrated 
a crucial pathogenic role for HB-EGF activation of glomerular 
EGFR signaling in a mouse model of anti-glomerular basement 
membrane (GBM)–induced RPGN. To what extent this signaling 
pathway is involved in the pathogenesis of other types of progres-
sive glomerulonephritis, such as IgA nephropathy, and of systemic 
diseases that can affect the glomerulus, such as lupus nephritis and 
diabetic nephropathy, would be worthwhile to study.
This important paper suggests therapeutic approaches to a 
severe renal disease (Figure), such as blocking the activation 
of EGFR by interfering with HB-EGF, by either preventing its 
release with ADAM inhibitors, or, as HB-EGF is the diphtheria 
toxin receptor, blocking its actions with the nontoxic diphtheria 
toxin analog CRM197. Finally, urinary HB-EGF might serve as 
a biomarker of glomerular disease activity.
Marc De Broe
Mice overexpressing BAFF develop 
a commensal flora–dependent, IgA-
associated nephropathy
McCarthy et al., J Clin Invest 2011; 121: 3991–4002; doi:10.1172/JCI45563
IgA nephropathy remains the most common form of glomeru-
lonephritis worldwide. Unfortunately, the exact pathophysiol-
ogy is not known, nor is a curative therapy available. Recently, 
analysis of patients with IgA nephritis or Henoch–Schönlein 
purpura nephritis revealed that their serum and mesangial 
deposits of IgA1 are galactose deficient, and that this IgA1 has 
a strong propensity to form macromolecular complexes that 
accumulate in the glomerular mesangium. The source of the 
abnormal IgA production has been variously speculated to 
involve mucosal tissues, tonsils, and bone marrow. Advances in 
elucidating the source and mechanisms of nephritis induction 
by the abnormal IgA1 have been hampered by the lack of mouse 
models, which in turn is due to major differences in the IgA 
system between mice and humans. Now McCarthy et al. report 
that serum IgA in BAFF-overexpressing mice is polymeric and 
underglycosylated. BAFF—B-cell activation factor of the TNF 
family—is a potent B-cell survival factor. The underglycosylated 
IgA is deposited in the glomerulus, which results in nephri-
tis. A role for IgA in the glomerulonephritis is supported, as 
BAFF transgenic (BAFF-Tg) mice with genetic deletion of IgA 
exhibited less renal pathology. Interestingly, a connection to the 
gut flora could be established, as the presence of commensal 
flora was essential for the elevated serum IgA phenotype, and, 
unexpectedly, commensal bacteria–reactive IgA antibodies were 
found in the blood. These data illustrate how excess B-cell sur-
vival signaling perturbs the normal balance with the microbiota, 
leading to a breach in the normal mucosal-peripheral compart-
mentalization. Such breaches may predispose the non-mucosal 
system to immune diseases such as IgA nephritis. Indeed, the 
authors found that a subset of patients with IgA nephropathy 
had elevated serum levels of a proliferation-inducing ligand 
(APRIL), a cytokine related to BAFF. These parallels between 
BAFF-Tg mice and human IgA nephropathy may provide a new 
framework to explore connections between mucosal environ-
ments, the mucosal immune system, and renal pathology in 
IgA nephritis. The model not only allows novel insights into 
the pathogenesis of IgA nephritis but may even point toward 
potential antibody therapy against B cell–activating factors such 
as APRIL and BAFF in IgA nephritis.
Detlef Schlöndorff 
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Activation of the EGFR pathway by HB-EGF in the glomerulus in 
RPGN. HB-EGF is expressed in the kidney in an anti-GBM disease model 
in mice. Bollée et al. now show that this molecule activates EGFR on 
podocytes and parietal epithelial cells to drive crescent formation 
during glomerulonephritis, renal failure, and the clinical features of 
RPGN. Blockade of the HB-EGF–EGFR axis with EGFR inhibitors or HB-EGF 
activity or release blockers may be a potential way of therapeutic 
intervention (Harris, Nat Med 2011; 17: 1188–1189).
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